CanariaBio Inc.
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
CanariaBio Inc Announces Enrollment Completion of randomized Phase 2 study of Oregovomab in combination with chemotherapy as neo-adjuvant treatment of patients with Advanced Ovarian Cancer 2024-08-23 20:00
CanariaBio and Hikma announce the signing of distribution and license agreement for oregovomab in MENA Region 2023-10-10 12:00
CanariaBio Achieves Significant Milestone with FDA's Orphan Drug Designation for MAb-AR20.5 Targeting Pancreatic Cancer 2023-08-21 20:00
1